Why Cingulate Shares Are Trading Higher Today

  • Cingulate Inc CING announced positive topline results from the CTx-1301-003 study assessing the effect of food on the absorption of its lead candidate CTx-1301. 
  • CTx-1301 is a trimodal, extended-release tablet formulation of dexmethylphenidate, a compound approved by the FDA for attention-deficit/hyperactivity disorder (ADHD).
  • The trial demonstrated that CTx-1301 could be taken with or without food. 
  • Multiple pharmacokinetic (PK) measurements were taken, and adverse events were consistent with previous findings and indicated a favorable tolerability profile.
  • "The study of CTx-1301 in the fasted versus fed state demonstrated that food did not delay absorption and thus should not affect the onset of action. Therefore, we expect that CTx-1301 can be administered orally with or without food," said Raul Silva, Chief Science Officer of Cingulate.
  • Cingulate recently initiated its first Phase 3 trial for CTx-1301, an adult dose-optimization efficacy and safety study to assess onset and duration, with results expected in Q3 of 2023
  • In addition, the company plans to initiate its pivotal Phase 3 trial study in pediatric and adolescent patients with ADHD in mid-2023.
  • Price Action: CING shares are up 68.5% at $1.87 during the premarket session on the last check Friday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareMoversGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!